Suzhou Abogen Biosciences Co., Ltd. is in talks with SoftBank Group Corp. (TSE:9984) ?and other investors to raise $300 million-$400 million, people familiar with the matter said. The fundraising by Abogen is in its final stages, although the sum may change, according to two people who declined to be named because the information is not public yet. It is not immediately clear how much SoftBank plans to invest, but a third person said the Japanese investment firm plans to lead the latest funding round. The Suzhou-based firm, which raised more than $700 million in August 2021 from investors including Singapore's state investor Temasek Holdings (TEM.UL) and Hillhouse-backed GL Ventures, targeted a valuation of about CNY 20 billion ($3.1 billion) prior to the current fundraising, one of the people said. SoftBank declined to comment. Abogen did not immediately reply to Reuters' requests for comment.